Decrease in depression symptoms is associated with longer survival in patients with metastatic breast cancer: A secondary analysis

Journal of Clinical Oncology

Volumn 29, Issue 4, 2011, Pages 413-420

  Giese Davis, Janine ^a   Collie, Kate ^a   Rancourt, Kate M S ^a   Neri, Eric ^a   Kraemer, Helena C ^a   Spiegel, David ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER SURVIVAL; COMORBIDITY; CONTROLLED STUDY; DEMOGRAPHY; DEPRESSION; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; METASTATIC BREAST CANCER; PATIENT EDUCATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SECONDARY ANALYSIS; SURVIVAL TIME;

ADULT; BREAST NEOPLASMS; DEPRESSION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PSYCHIATRIC STATUS RATING SCALES; QUALITY OF LIFE; RISK ASSESSMENT; RISK FACTORS; SELF-HELP GROUPS; SURVIVORS; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 79551570998     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.28.4455     Document Type: Article

References (89)

1. Satin JR, Linden W, Phillips MJ: Depression as a predictor of disease progression and mortality in cancer patients: A meta-analysis. Cancer 115: 5349-5361, 2009
2. Fawzy FI, Fawzy NW, Hyun CS, et al: Malignant melanoma: Effects of an early structured psychiatric intervention, coping, and affective state on recurrence and survival 6 years later. Arch Gen Psychiatry 50:681-689, 1993 (Pubitemid 23263804)
3. Spiegel D, Butler LD, Giese-Davis J, et al: Effects of supportive-expressive group therapy on survival of patients with metastatic breast cancer: A randomized prospective trial. Cancer 110:1130-1138, 2007 (Pubitemid 47312880)
4. Andersen BL, Yang HC, Farrar WB, et al: Psychologic intervention improves survival for breast cancer patients: A randomized clinical trial. Cancer 113:3450-3458, 2008
5. Goodwin PJ, Leszcz M, Ennis M, et al: The effect of group psychosocial support on survival in metastatic breast cancer. N Engl J Med 345:1719-1726, 2001
6. Andersen BL, Thornton LM, Shapiro CL, et al: Biobehavioral, immune, and health benefits following recurrence for psychological intervention participants. Clin Cancer Res 16:3270-3278, 2010
7. Giese-Davis J, Spiegel D: Emotional expression and cancer progression, in Davidson RJ, Scherer KR, Hill Goldsmith H (eds): Handbook of Affective Sciences: Series in Affective Science. Oxford, United Kingdom, Oxford University Press, 2003, pp 1053-1082
8. Falagas ME, Zarkadoulia EA, Ioannidou EN, et al: The effect of psychosocial factors on breast cancer outcome: A systematic review. Breast Cancer Res 9:R44, 2007
9. Spiegel D, Giese-Davis J: Depression and cancer: Mechanisms and disease progression. Biol Psychiatry 54:269-282, 2003 (Pubitemid 37267857)
10. Hilakivi-Clarke L, Rowland J, Clarke R, et al: Psychosocial factors in the development and progression of breast cancer. Breast Cancer Res Treat 29:141-160, 1994 (Pubitemid 24112616)
11. Armaiz-Pena GN, Lutgendorf SK, Cole SW, et al: Neuroendocrine modulation of cancer progression. Brain Behav Immun 23:10-15, 2009
12. Petticrew M, Bell R, Hunter D: Influence of psychological coping on survival and recurrence in people with cancer: Systematic review. BMJ 325: 1066, 2002
13. Spiegel D, Bloom JR, Kraemer HC, et al: Effect of psychosocial treatment on survival of patients with metastatic breast cancer. Lancet 2:888-891, 1989
14. Kissane DW, Love A, Hatton A, et al: Effect of cognitive-existential group therapy on survival in early-stage breast cancer. J Clin Oncol 22:4255-4260, 2004 (Pubitemid 41185146)
15. Kissane DW, Grabsch B, Clarke DM, et al: Supportive-expressive group therapy for women with metastatic breast cancer: Survival and psychosocial outcome from a randomized controlled trial. Psychooncology 16:277-286, 2007 (Pubitemid 46681097)
16. Onitilo AA, Nietert PJ, Egede LE: Effect of depression on all-cause mortality in adults with cancer and differential effects by cancer site. Gen Hosp Psychiatry 28:396-402, 2006 (Pubitemid 44572113)
17. Lutgendorf SL, Lamkin DM, DeGeest K, et al: Depressed and anxious mood and T-cell cytokine expressing populations in ovarian cancer patients. Brain Behav Immun 22:890-900, 2008
18. Lutgendorf SK, Weinrib AZ, Penedo F, et al: Interleukin-6, cortisol, and depressive symptoms in ovarian cancer patients. J Clin Oncol 26:4820-4827, 2008
19. Giese-Davis J, Wilhelm FH, Conrad A, et al: Depression and stress reactivity in metastatic breast cancer. Psychosom Med 68:675-683, 2006 (Pubitemid 44454635)
20. Thornton LM, Andersen BL, Schuler TA, et al: A psychological intervention reduces inflammatory markers by alleviating depressive symptoms: Secondary analysis of a randomized controlled trial. Psychosom Med 71:715-724, 2009
21. Pyter LM, Pineros V, Galang JA, et al: Peripheral tumors induce depressive-like behaviors and cytokine production and alter hypothalamic- pituitary-adrenal axis regulation. Proc Natl Acad Sci U S A 106:9069-9074, 2009
22. Massie MJ: Prevalence of depression in patients with cancer. J Natl Cancer Inst Monogr 32: 57-71, 2004
23. Kissane DW, Grabsch B, Love A, et al: Psychiatric disorder in women with early stage and advanced breast cancer: A comparative analysis. Aust N Z J Psychiatry 38:320-326, 2004 (Pubitemid 38765232)
24. Breen S, Baravelli C, Schofield P, et al: Is symptom burden a predictor of anxiety and depression in patients with cancer about to commence chemotherapy? Med J Aust 190:S99-S104, 2009 (suppl)
25. Banou E, Hobfoll SE, Trochelman RD: Loss of resources as mediators between interpersonal trauma and traumatic and depressive symptoms among women with cancer. J Health Psychol 14: 200-214, 2009
26. Gandubert C, CarrièreI, Escot C, et al: Onset and relapse of psychiatric disorders following early breast cancer: A case-control study. Psychooncology 18:1029-1037, 2009
27. Lehto US, Ojanen M, Dyba T, et al: Baseline psychosocial predictors of survival in localised breast cancer. Br J Cancer 94:1245-1252, 2006
28. Goodwin PJ, Ennis M, Bordeleau LJ, et al: Health-related quality of life and psychosocial status in breast cancer prognosis: Analysis of multiple variables. J Clin Oncol 22:4184-4192, 2004 (Pubitemid 41185189)
29. Tross S, Herdon J 2nd, Korzun A, et al: Psychological symptoms and disease-free and overall survival in women with stage II breast cancer. J Natl Cancer Inst 88:661-667, 1996 (Pubitemid 26152552)
30. Phillips KA, Osborne RH, Giles GG, et al: Psychosocial factors and survival of young women with breast cancer: A population-based prospective cohort study. J Clin Oncol 26:4666-4671, 2008
31. Goodwin JS, Zhang DD, Ostir GV: Effect of depression on diagnosis, treatment, and survival of older women with breast cancer. J Am Geriatr Soc 52:106-111, 2004 (Pubitemid 38090398)
32. Efficace F, Therasse P, Piccart MJ, et al: Health-related quality of life parameters as prognostic factors in a nonmetastatic breast cancer population: An international multicenter study. J Clin Oncol 22:3381-3388, 2004 (Pubitemid 41103697)
33. Efficace F, Biganzoli L, Piccart M, et al: Baseline health-related quality-of-life data as prognostic factors in a phase III multicentre study of women with metastatic breast cancer. Eur J Cancer 40: 1021-1030, 2004 (Pubitemid 38496258)
34. Watson M, Haviland JS, Greer S, et al: Influence of psychological response on survival in breast cancer: A population-based cohort study. Lancet 354:1331-1336, 1999 (Pubitemid 29481628)
35. Hjerl K, Andersen EW, Keiding N, et al: Depression as a prognostic factor for breast cancer mortality. Psychosomatics 44:24-30, 2003 (Pubitemid 36050569)
36. Groenvold M, Petersen MA, Idler E, et al: Psychological distress and fatigue predicted recurrence and survival in primary breast cancer patients. Breast Cancer Res Treat 105:209-219, 2007 (Pubitemid 47366885)
37. Jamison RN, Burish TG, Wallston KA: Psychogenic factors in predicting survival of breast cancer patients. J Clin Oncol 5:768-772, 1987 (Pubitemid 17120254)
38. Levy SM, Herberman RB, Lippman M, et al: Immunological and psychosocial predictors of disease recurrence in patients with early-stage breast cancer. Behav Med 17:67-75, 1991
39. Penninx BW, Guralnik JM, Pahor M, et al: Chronically depressed mood and cancer risk in older persons. J Natl Cancer Inst 90:1888-1893, 1998
40. Derogatis LR, Abeloff MD, Melisaratos N: Psychological coping mechanisms and survival time in metastatic breast cancer. JAMA 242:1504-1508, 1979 (Pubitemid 10243607)
41. Weihs KL, Enright TM, Simmens SJ, et al: Negative affectivity, restriction of emotions, and site of metastases predict mortality in recurrent breast cancer. J Psychosom Res 49:59-68, 2000
42. Dean C, Surtees PG: Do psychological factors predict survival in breast cancer? J Psychosom Res 33:561-569, 1989
43. Jensen MR: Psychobiological factors predicting the course of breast cancer. J Pers 55:317-342, 1987
44. Gidron Y, Perry H, Glennie M: Does the vagus nerve inform the brain about preclinical tumours and modulate them? Lancet Oncol 6:245-248, 2005
45. Sephton SE, Dhabhar FS, Keuroghlian AS, et al: Depression, cortisol, and suppressed cell-mediated immunity in metastatic breast cancer. Brain Behav Immun 23:1148-1155, 2009
46. Posener JA, DeBattista C, Williams GH, et al: 24-Hour monitoring of cortisol and corticotropin secretion in psychotic and nonpsychotic major depression. Arch Gen Psychiatry 57:755-760, 2000 (Pubitemid 30650110)
47. Raison CL, Miller AH: The neuroimmunology of stress and depression. Semin Clin Neuropsychiatry 6:277-294, 2001
48. DiMatteo MR, Lepper HS, Croghan TW: Depression is a risk factor for noncompliance with medical treatment: Meta-analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med 160:2101-2107, 2000 (Pubitemid 30482715)
49. DiMatteo MR, Haskard KB, Williams SL: Health beliefs, disease severity, and patient adherence: A meta-analysis. Med Care 45:521-528, 2007
50. Raison CL, Giese-Davis J, Miller AH, et al: Depression in cancer: Mechanisms, consequences and treatment, in Evans DL, Charney DS, Lewis L (eds): The Physician's Guide to Depression and Bipolar Disorders. New York, NY, McGraw-Hill, 2006, pp 377-410
51. Zucker TL, Samuelson KW, Muench F, et al: The effects of respiratory sinus arrhythmia biofeedback on heart rate variability and posttraumatic stress disorder symptoms: A pilot study. Appl Psychophysiol Biofeedback 34:135-143, 2009
52. Holsboer F: Stress, hypercortisolism and corticosteroid receptors in depression: Implications for therapy. J Affect Disord 62:77-91, 2001
53. Andersen BL, Farrar WB, Golden-Kreutz DM, et al: Psychological, behavioral, and immune changes after a psychological intervention: A clinical trial. J Clin Oncol 22:3570-3580, 2004 (Pubitemid 41103664)
54. Giese-Davis J, Koopman C, Butler LD, et al: Change in emotion-regulation strategy for women with metastatic breast cancer following supportive-expressive group therapy. J Consult Clin Psychol 70:916-925, 2002 (Pubitemid 34847980)
55. Radloff LS: The CES-D Scale: A self-report depression scale for research in the general population. Appl Psychol Measurement 1:385-401, 1977
56. Contrada RJ, Boulifard DA, Idler EL, et al: Course of depressive symptoms in patients undergoing heart surgery: Confirmatory analysis of the factor pattern and latent mean structure of the Center for Epidemiologic Studies Depression Scale. Psychosom Med 68:922-930, 2006 (Pubitemid 44808718)
57. Hann D, Winter K, Jacobsen P: Measurement of depressive symptoms in cancer patients: Evaluation of the Center for Epidemiological Studies Depression Scale (CES-D). J Psychosom Res 46:437-443, 1999 (Pubitemid 29277215)
58. Classen C, Butler LD, Koopman C, et al: Supportive-expressive group therapy and distress in patients with metastatic breast cancer: A randomized clinical intervention trial. Arch Gen Psychiatry 58:494-501, 2001 (Pubitemid 32411331)
59. Butler LD, Koopman C, Neri E, et al: Effects of supportive-expressive therapy on pain in women with metastatic breast cancer. Health Psychol 28: 579-587, 2009
60. Gibbons RD, Hedeker D, Waternaux C, et al: Some conceptual and statistical issues in the analysis of longitudinal psychiatric data. Arch Gen Psychiatry 50:739-750, 1993
61. Kraemer HC, Blasey CM: Centring in regression analyses: A strategy to prevent errors in statistical inference. Int J Methods Psychiatr Res 13:141-151, 2004 (Pubitemid 39264454)
62. Butler LD, Koopman C, Cordova MJ, et al: Psychological distress and pain significantly increase before death in metastatic breast cancer patients. Psychosom Med 65:416-426, 2003 (Pubitemid 36628895)
63. Thombs BD, Hudson M, Schieir O, et al: Reliability and validity of the Center for Epidemiologic Studies Depression Scale in patients with systemic sclerosis. Arthritis Rheum 59:438-443, 2008 (Pubitemid 351399215)
64. Frasure-Smith N, Lespérance F: Depression and cardiac risk: Present status and future directions. Heart 96:173-176, 2010
65. Frasure-Smith N, Lespérance F, Irwin MR, et al: The relationships among heart rate variability, inflammatory markers and depression in coronary heart disease patients. Brain Behav Immun 23:1140-1147, 2009
66. Miller AH, Maletic V, Raison CL: Inflammation and its discontents: The role of cytokines in the pathophysiology of major depression. Biol Psychiatry 65:732-741, 2009
67. Gidron Y, Ronson A: Psychosocial factors, biological mediators, and cancer prognosis: A new look at an old story. Curr Opin Oncol 20:386-392, 2008
68. Gidron Y, Kupper N, Kwaijtaal M, et al: Vagusbrain communication in atherosclerosis-related inflammation: A neuroimmunomodulation perspective of CAD. Atherosclerosis 195:e1-e9, 2007 (Pubitemid 350087943)
69. Riordan WP Jr, Norris PR, Jenkins JM, et al: Early loss of heart rate complexity predicts mortality regardless of mechanism, anatomic location, or severity of injury in 2178 trauma patients. J Surg Res 156:283-289, 2009
70. Mravec B, Gidron Y, Kukanova B, et al: Neuralendocrine- immune complex in the central modulation of tumorigenesis: Facts, assumptions, and hypotheses. J Neuroimmunol 180:104-116, 2006 (Pubitemid 44692318)
71. Mravec B, Gidron Y, Hulin I: Neurobiology of cancer: Interactions between nervous, endocrine and immune systems as a base for monitoring and modulating the tumorigenesis by the brain. Semin Cancer Biol 18:150-163, 2008
72. Abercrombie HC, Giese-Davis J, Sephton S, et al: Flattened cortisol rhythms in metastatic breast cancer patients. Psychoneuroendocrinology 29:1082-1092, 2004 (Pubitemid 38833536)
73. Sephton SE, Sapolsky RM, Kraemer HC, et al: Diurnal cortisol rhythm as a predictor of breast cancer survival. J Natl Cancer Inst 92:994-1000, 2000 (Pubitemid 30469965)
74. Pruessner M, Hellhammer DH, Pruessner JC, et al: Self-reported depressive symptoms and stress levels in healthy young men: Associations with the cortisol response to awakening. Psychosom Med 65:92-99, 2003 (Pubitemid 36143201)
75. Spiegel D, Giese-Davis J, Taylor CB, et al: Stress sensitivity in metastatic breast cancer: Analysis of hypothalamic-pituitary-adrenal axis function. Psychoneuroendocrinology 31:1231-1244, 2006 (Pubitemid 44792371)
76. Meyers CA: Mood and cognitive disorders in cancer patients receiving cytokine therapy. Adv Exp Med Biol 461:75-81, 1999
77. Van Gool AR, Kruit WHJ, Cornelissen JJ, et al: Management of psychiatric adverse events with immunotherapy with interferon-alfa. Acta Neuropsychiatr 11:120-124, 1999
78. Bonaccorso S, Meltzer H, Maes M: Psychological and behavioural effects of interferon-alpha. Curr Opin Psychiatry 13:673-677, 2000
79. Yirmiya R: Depression in medical illness: The role of the immune system. West J Med 173:333-336, 2000
80. Maes M, Bosmans E, Meltzer HY: Immunoendocrine aspects of major depression: Relationships between plasma interleukin-6 and soluble interleukin-2 receptor, prolactin and cortisol. Eur Arch Psychiatry Clin Neurosci 245:172-178, 1995
81. Maes M: Major depression and activation of the inflammatory response system. Adv Exp Med Biol 461:25-46, 1999
82. Warr D, Street J, Carides A: Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: Analysis of phase 3 trial of aprepitant in patients receiving Adriamycin- cyclophosphamide-based chemotherapy. Support Care Cancer [epub ahead of print on May 13, 2010]
83. Sephton S, Spiegel D: Circadian disruption in cancer: A neuroendocrine-immune pathway from stress to disease? Brain Behav Immun 17:321-328, 2003
84. Andersen BL, Farrar WB, Golden-Kreutz D, et al: Distress reduction from a psychological intervention contributes to improved health for cancer patients. Brain Behav Immun 21:953-961, 2007 (Pubitemid 47299295)
85. Whitlock FA, Sisking M: Depression and cancer: A follow-up study. Psychol Med 9:747-752, 1979 (Pubitemid 10157602)
86. Gill D, Hatcher S: Antidepressants for depression in people with physical illness. Cochrane Database Syst Rev 2:CD001312, 2000
87. Barsevick AM, Sweeney C, Haney E, et al: A systematic qualitative analysis of psychoeducational interventions for depression in patients with cancer. Oncol Nurs Forum 29:73-84, 2002
88. Gallo JJ, Bogner HR, Morales KH, et al: The effect of a primary care practice-based depression intervention on mortality in older adults: A randomized trial. Ann Intern Med 146:689-698, 2007
89. Akechi T, Okuyama T, Onishi J, et al: Psychotherapy for depression among incurable cancer patients. Cochrane Database Syst Rev 2:CD005537, 2008